DiscoveRx Provides PathHunter™ Technology to NIH
News Nov 04, 2005
DiscoveRx has announced that it has signed an agreement with the National Institutes of Health which will provide initial access to their PathHunter technology for small molecule screening against selected targets of interest to the Molecular Libraries Roadmap Initiative.
PathHunter is a cell-based assay technology ideally suited to high throughput screening that monitors cell signaling pathways.
The movement of proteins is monitored in a homogenous assay format within the cell using positional complementation.
This approach has been applied to a range of target molecules of interest to drug discovery, including kinases, transcription factors, phosphatases and nuclear hormone receptors, and offers a convenient, non-imaging assay format that is amenable to high throughput automation systems.
“We are very pleased to be working with the NIH Chemical Genomics Center to help accelerate their screening efforts,” stated Dr. Richard Eglen, CSO of DiscoveRx.
“We believe that our technology addresses many of the key benefits of more complex cell-based assays that employ imaging, but in a format specifically optimized for higher throughput screening campaigns.”
“Our EFC technology is a proven in vitro biochemical screening method, and the PathHunter products now apply this technology in a novel, whole-cell assay.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.